Skip to main content
. 2021 Jul 22;6(14):e145875. doi: 10.1172/jci.insight.145875

Figure 3. DX1 localizes to orthotopic GBM tumors in a DP-sensitive manner.

Figure 3

Human GBM model 1 GSCs engineered to express luciferase were inoculated into the brains of immunodeficient mice (n = 10) to generate orthotopic PDX GBM tumors. (A) Representative IVIS images confirming presence of tumors (upper panel) and comparing DX1 localization to tumors (lower panel). DX1 was labeled with AF750 to facilitate its detection by IVIS. Mice were treated with i.v. and i.p. control buffer (n = 2), i.v. DX1AF750 (20 mg/kg) and i.p. control buffer (n = 4), or i.v. DX1AF750 (20 mg/kg) and i.p. DP (70 mg/kg) (n = 4). IVIS measurements 24 hours after treatment demonstrated DX1 localization into the tumors, and DP significantly suppressed this uptake. (B) Quantification of radiance efficiencies. *P = 0.0142, **P < 0.0001. Tukey’s multiple-comparison test–adjusted P values; numbers of mice evaluated at each point are indicated in the plots.